This project is a collaborative arrangement among investigators who are active in clinical and basic research work on the paradigm arterial thrombotic disease, thrombotic thrombocytopenic purpura (TTP). The investigators have access to patients with TTP and clinically related syndromes in the public, private and government hospitals of 3 large population centers. Although geographically separate, the investigators have a close, productive working association. They also have developed a network of clinical research interactions with physicians involved in the care of these patients in other parts of the U.S.A. The project is focused on the role of von Willebrand factor (vWF) multimers in the pathophysiology of relapsing and non-relapsing types of TTP. The association between plasma vWF multimer abnormalities and other disorders clinically related to TTP (e.g., the hemolytic-uremic syndrome), and between abnormal vWF forms and defects in prostacyclin (PGI2) production and stabilization will also be examined. The experimental work includes: development of a test system for acute TTP; identification of a """"""""vWF cofactor"""""""" present in blood during acute TTP episodes; isolation and characterization of the unusually large vWF multimers produced by endothelial cells and found in the plasma of chronic relapsing TTP patients; isolation and characterization of the """"""""unusually large vWF converting activity"""""""" in normal cryosupernatant; and evaluation of the hypothesis that the relapsing form of TTP is a disease of aberrant immune regulation. We expect that more effective prophylaxis and therapy for TTP will emerge from the work proposed. We anticipate that the results will be applicable to the study of common arterial thrombotic disorders involving regions of the coronary or cerebrovascular circulation. We also expect that the results of our study will make possible molecular level on TTP and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL035387-04
Application #
3349228
Study Section
(SRC)
Project Start
1986-04-01
Project End
1991-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Wu, K K (1997) Regulation of prostaglandin H synthase-1 gene expression. Adv Exp Med Biol 400A:121-6
Zoldhelyi, P; McNatt, J; Xu, X M et al. (1996) Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 93:10-7
Xu, X M; Tang, J L; Hajibeigi, A et al. (1996) Transcriptional regulation of endothelial constitutive PGHS-1 expression by phorbol ester. Am J Physiol 270:C259-64
Wu, K K (1996) Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. J Formos Med Assoc 95:661-6
Xu, X M; Hajibeige, A; Tazawa, R et al. (1995) Characterization of human prostaglandin H synthase genes. Adv Prostaglandin Thromboxane Leukot Res 23:105-7
Tang, J L; Zembowicz, A; Xu, X M et al. (1995) Role of Sp1 in transcriptional activation of human nitric oxide synthase type III gene. Biochem Biophys Res Commun 213:673-80
Matijevic-Aleksic, N; Sanduja, S K; Wang, L H et al. (1995) Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta 1269:167-75
Wu, K K (1995) Molecular regulation and augmentation of prostacyclin biosynthesis. Agents Actions Suppl 45:11-7
Tazawa, R; Xu, X M; Wu, K K et al. (1994) Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 203:190-9
Wang, L H; Tazawa, R; Lang, A Q et al. (1994) Alternate splicing of human thromboxane synthase mRNA. Arch Biochem Biophys 315:273-8

Showing the most recent 10 out of 43 publications